245 related articles for article (PubMed ID: 26368308)
1. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.
Pala F; Morbach H; Castiello MC; Schickel JN; Scaramuzza S; Chamberlain N; Cassani B; Glauzy S; Romberg N; Candotti F; Aiuti A; Bosticardo M; Villa A; Meffre E
J Clin Invest; 2015 Oct; 125(10):3941-51. PubMed ID: 26368308
[TBL] [Abstract][Full Text] [Related]
2. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
[TBL] [Abstract][Full Text] [Related]
3. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans.
Castiello MC; Bosticardo M; Pala F; Catucci M; Chamberlain N; van Zelm MC; Driessen GJ; Pac M; Bernatowska E; Scaramuzza S; Aiuti A; Sauer AV; Traggiai E; Meffre E; Villa A; van der Burg M
J Autoimmun; 2014 May; 50(100):42-50. PubMed ID: 24369837
[TBL] [Abstract][Full Text] [Related]
4. The ups and downs of negative (and positive) selection of B cells.
Weill JC; Reynaud CA
J Clin Invest; 2015 Oct; 125(10):3748-50. PubMed ID: 26368305
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.
Bosticardo M; Draghici E; Schena F; Sauer AV; Fontana E; Castiello MC; Catucci M; Locci M; Naldini L; Aiuti A; Roncarolo MG; Poliani PL; Traggiai E; Villa A
J Allergy Clin Immunol; 2011 Jun; 127(6):1376-84.e5. PubMed ID: 21531013
[TBL] [Abstract][Full Text] [Related]
7. Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome.
Kolhatkar NS; Brahmandam A; Thouvenel CD; Becker-Herman S; Jacobs HM; Schwartz MA; Allenspach EJ; Khim S; Panigrahi AK; Luning Prak ET; Thrasher AJ; Notarangelo LD; Candotti F; Torgerson TR; Sanz I; Rawlings DJ
J Exp Med; 2015 Sep; 212(10):1663-77. PubMed ID: 26371186
[TBL] [Abstract][Full Text] [Related]
8. Effects of Wiskott-Aldrich Syndrome Protein Deficiency on IL-10-Producing Regulatory B Cells in Humans and Mice.
Du HQ; Zhang X; An YF; Ding Y; Zhao XD
Scand J Immunol; 2015 Jun; 81(6):483-93. PubMed ID: 25728049
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.
Braun CJ; Boztug K; Paruzynski A; Witzel M; Schwarzer A; Rothe M; Modlich U; Beier R; Göhring G; Steinemann D; Fronza R; Ball CR; Haemmerle R; Naundorf S; Kühlcke K; Rose M; Fraser C; Mathias L; Ferrari R; Abboud MR; Al-Herz W; Kondratenko I; Maródi L; Glimm H; Schlegelberger B; Schambach A; Albert MH; Schmidt M; von Kalle C; Klein C
Sci Transl Med; 2014 Mar; 6(227):227ra33. PubMed ID: 24622513
[TBL] [Abstract][Full Text] [Related]
10. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome.
Adriani M; Aoki J; Horai R; Thornton AM; Konno A; Kirby M; Anderson SM; Siegel RM; Candotti F; Schwartzberg PL
Clin Immunol; 2007 Jul; 124(1):41-8. PubMed ID: 17512803
[TBL] [Abstract][Full Text] [Related]
11. N-WASP is required for B-cell-mediated autoimmunity in Wiskott-Aldrich syndrome.
Volpi S; Santori E; Abernethy K; Mizui M; Dahlberg CI; Recher M; Capuder K; Csizmadia E; Ryan D; Mathew D; Tsokos GC; Snapper S; Westerberg LS; Thrasher AJ; Candotti F; Notarangelo LD
Blood; 2016 Jan; 127(2):216-20. PubMed ID: 26468226
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
[TBL] [Abstract][Full Text] [Related]
15. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.
Sereni L; Castiello MC; Di Silvestre D; Della Valle P; Brombin C; Ferrua F; Cicalese MP; Pozzi L; Migliavacca M; Bernardo ME; Pignata C; Farah R; Notarangelo LD; Marcus N; Cattaneo L; Spinelli M; Giannelli S; Bosticardo M; van Rossem K; D'Angelo A; Aiuti A; Mauri P; Villa A
J Allergy Clin Immunol; 2019 Sep; 144(3):825-838. PubMed ID: 30926529
[TBL] [Abstract][Full Text] [Related]
19. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
Galy A; Roncarolo MG; Thrasher AJ
Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.
Hacein-Bey Abina S; Gaspar HB; Blondeau J; Caccavelli L; Charrier S; Buckland K; Picard C; Six E; Himoudi N; Gilmour K; McNicol AM; Hara H; Xu-Bayford J; Rivat C; Touzot F; Mavilio F; Lim A; Treluyer JM; Héritier S; Lefrère F; Magalon J; Pengue-Koyi I; Honnet G; Blanche S; Sherman EA; Male F; Berry C; Malani N; Bushman FD; Fischer A; Thrasher AJ; Galy A; Cavazzana M
JAMA; 2015 Apr; 313(15):1550-63. PubMed ID: 25898053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
